Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).

Transplant infectious disease : an official journal of the Transplantation Society - 1 Oct 2018

Chong Pearlie P, Teiber Dagny, Prokesch Bonnie C, Arasaratnam Reuben J, Peltz Matthias, Drazner Mark H, Garg Sonia

Abstract excerpt

Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetates
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytomegalovirus Infections

Share to Ganciclovir

Share to Heart Transplantation

Share to Phosphotransferases (Alcohol Group Acceptor)

Share to Quinazolines

Share to Secondary Prevention

Source

Identifiers

PMID: 29989279
DOI: 10.1111/tid.12965

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).PMID 29989279Read ↗

Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.Semantic proximity Read ↗

Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.Semantic proximity Read ↗

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experienceSemantic proximity Read ↗

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationSemantic proximity Read ↗

Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.Semantic proximity Read ↗

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationSemantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

Revealing the Unseen: Next-Generation Sequencing for Early Detection of Drug-Resistant Cytomegalovirus Variants Upon Letermovir Prophylaxis FailureSemantic proximity Read ↗

Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis.Semantic proximity Read ↗

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.Semantic proximity Read ↗

Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir ProphylaxisSemantic proximity Read ↗

In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.